Source comparison
Bioavailability vs Subcutaneous Injection
MOTS-c intranasal research consistently shows lower absolute bioavailability than subcutaneous injection. But the pharmacokinetic profile tells a more nuanced story. Subcutaneous MOTS-c injection achieves 70–85% bioavailability with a time-to-peak (Tmax) of 45
This comparison does not assign a generated winner or score.
- MOTS-c intranasal research consistently shows lower absolute bioavailability than subcutaneous injection. But the pharmacokinetic profile tells a more nuanced story. Subcutaneous MOTS-c injection achieves 70–85% bioavailability with a time-to-peak (Tmax) of 45–90 minutes, followed by hepatic first-pass metabolism that reduces active circulating peptide by 30–50% before reaching mitochondrial targets in skeletal muscle, liver, and adipose tissue.
- Intranasal administration delivers 40–60% of the administered dose to systemic circulation, but Tmax occurs at 15–30 minutes. Half the time of injection. More critically, the peptide bypasses hepatic degradation on first pass, meaning the proportion of active, unmetabolised MOTS-c reaching target tissues is comparable to injection despite lower absolute absorption. Research from Lochhead and Thorne (Drug Delivery and Translational Research, 2012) demonstrated this principle with other mitochondrial peptides: intranasal delivery produced equivalent tissue concentrations at 60% the subcutaneous dose because hepatic clearance was avoided.
- The intranasal route also produces a more favourable CNS:plasma ratio. MOTS-c crosses into cerebrospinal fluid (CSF) at concentrations 3–5 times higher via intranasal delivery than via subcutaneous injection, which matters when studying hypothalamic metabolic signalling. One of MOTS-c's primary mechanisms. Our experience with research teams using both routes shows that intranasal protocols require dose adjustments (typically 1.5× the subcutaneous dose) to achieve equivalent systemic exposure, but the faster onset and enhanced CNS penetration make it the preferred route for studies targeting central metabolic regulation.